Biotech Theravance (NASDAQ: THRX) is undergoing a radical transformation. Is this special situation a unique opportunity for dividend investors, or arre problems lurking beneath the surface.
Theravance recently split in two, with the money it earns fromsucessful COPD drugs continuing under the old ticker and paid out as a juicy dividend, while the drug-development arm is reborn as Theravance Biopharma.
In this video, Motley Fool Healthcare analyst David Williamson evaluates the dividend stock using a World Cup inspired grading system: a yellow card is a warning for investors, a red card is an ejection, and a "goal" happens if the stock looks like a winner.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.